D r Jonathan
Rees discusses what not to do in primary care urology. All guidelines provide a general framework for medical practitioners to aid decision-making in diagnosis and management of patients. However, rather than focusing on 'what not to do routinely' based on guidelines, the medical decision-making process has to focus on 'when to do what' based on individual patients, especially in primary care urology.
LUTS/BPH
A good history and examination are imperative in diagnosis and management of LUTS/BPH, as in all other avenues in medicine. The symptoms of LUTS or BPH do not always correlate well with objective measurements. Thus all guidelines highlight the importance of a good history and examination. DRE remains a valuable yet poorly utilised tool, which could give an indication of prostate size and any malignant features in men with LUTS.
Urinalysis is another useful, non-expensive first-line essential tool, which should be used in patients with LUTS. Although urine flow should be used only in select patients, postvoid residuals should be used as a first-line measure in men with LUTS, as recommended by the European Association of Urology (EAU) guidelines. 1 The findings from the history, examination and first-line investigations would then guide the need for measurement of creatinine and upper tract imaging in patients with LUTS/BPH as well as treatment and, if needed, referral to a urologist.
PSA TESTING
When to do a PSA test is the million-dollar question. Routine addition of PSA testing to a battery of tests can have significant impact on an individual as well as society level, especially as routine PSA screening can lead to overdiagnosis of insignificant cancers, especially in younger men (<55 years). In an era where the mortality benefit by PSA testing in asymptomatic men remains inconclusive and there are harms associated with overtreatment, patients should be carefully selected and should not be offered testing without an in-depth discussion to ensure they understand the possible outcomes.
NON-VISIBLE HAEMATURIA
In the UK, significant NVH is defined as 'urine dipstick of a fresh voided urine sample, containing no preservative, with 1+ of blood or greater', according to the joint consensus statement on haematuria by the Renal Association and the British Association of Urological Surgeons in 2008. 2 They recommend that all patients with symptomatic NVH (ie presence of LUTS) and patients ≥40 years with asymptomatic haematuria need urology referral for further investigation.
2 Routine microscopy is discouraged for confirmation of dipstick haematuria because of significant falsenegative rates with intensive labour processes; in addition, microscopy adds little value to establishing the diagnosis of haematuria. 2 Conversely, the American Urological Association (AUA) guidelines define NVH or asymptomatic microhaematuria (AMH) as three or more red blood cells per highpowered field on a properly collected urinary specimen in the absence of an obvious benign cause. 3 They go on to state specifically that positive dipstick does not define AMH/NVH, and a positive dipstick reading then requires microscopic examination to confirm or refute the diagnosis of AMH. 3 Therefore in the USA, confirmation by microscopic examination after a positive dipstick is essential prior to referral to urology, as up to 75 per cent of NVH can be due to dipstick pseudohaematuria and is shown to be highly cost-ineffective. 4 The AUA guidelines further highlight the necessity of a thorough history and examination to exclude other causes of NVH, followed by further investigation with renal function and radiological evaluation, preferably with multiphasic CT urography. 3 These patients are then referred on for an urgent urology evaluation by means of a haematuria clinic, even in the presence of clinical indicators suspicious for renal parenchymal disease such as proteinuria, casts and renal insufficiency or NVH in patients taking anticoagulation. The AUA guidelines also state that patients with NVH due to UTI require a repeat microscopic evaluation after the infection is treated.
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STERILE PYURIA
Even though sterile pyuria is the classic finding in TB, a number of infective (chlamydia, ureaplasma, viral, fungal, etc), inflammatory (prostatitis, etc) and benign and malignant conditions can also account for sterile pyuria. Therefore the investigations should be directed toward the history and examination findings. As Dr Rees states, screening for TB should not be the initial process in a patient with no risk factors or features, although this should not be forgotten.
ERECTILE DYSFUNCTION
Testosterone replacement therapy can be helpful in hypogonadal patients with erectile dysfunction, but should be used after other endocrinological causes for testicular failure have been excluded. 5 As Dr Rees states, in patients with normal testosterone levels, testosterone replacement therapy is not indicated. 6 It should also be noted that testosterone therapy is contraindicated for patients with untreated prostate cancer or unstable cardiac disease and its use is controversial in men with a history of prostate cancer. Therefore DRE, serum PSA test, hematocrit, liver function tests and lipid profile are advocated by EAU guidelines.
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INCONTINENCE
The impact of lifestyle modifications and pelvic floor exercises in stress incontinence should not be underestimated as first-line therapy. Duloxetine increases the resting tone and contraction strength of the urethral striated sphincter by inhibition of presynaptic reuptake of the neurotransmitters, serotonin and norepinephrine. It is important to highlight that, although duloxetine improves stress and mixed urinary incontinence, it does not cure stress incontinence. 7 Therefore identifying the patient's expectations may help decide if duloxetine is an option, if improvement rather than cure is the aim. Furthermore, as Dr Rees points out, duloxetine is poorly tolerated because of its side-effects and this should be discussed with the patient as well prior to initiating this and the dose needs to be titrated up. 7 Although anticholinergics are very effective in urge incontinence, they are generally poorly tolerated because of side-effects, with more than half of patients stopping the medication within the first three months. 7 The recent introduction of mirabegron has provided an alternative option, demonstrating cure or improvement in urge incontinence with milder sideeffects. 7 Therefore the use of mirabegron could be justified as an alternative to anticholinergics, provided that the patient understands that the possible long-term side-effects are still unknown.
CHRONIC PROSTATITIS
The occurrence of persistent or recurrent episodic pain reproduced by prostate palpation is no longer termed 'chronic prostatitis' and belongs to the more complex spectrum of chronic pelvic pain syndrome of the male. Many feel that these terms should not be used interchangeably, as only 10 per cent have a proven bacterial infection. 8 It is beyond the scope of this article to discuss the complexities involved in managing this condition, which usually involves a multimodality and multidisciplinary approach. However, the EAU guidelines state that it may be appropriate to maintain patients who respond to an initial course of antibiotics on a four-to six-week course, or even longer. Other therapeutic options should be offered to those who do not respond to one unsuccessful course of a quinolone or tetracycline antibiotic over six weeks. 8 Furthermore, urine culture, leukocyte and antibody status of prostate-specific specimens are poor predictors of antibiotic response in patients with chronic pelvic pain syndrome. 8 
